eGenesis

Congratulations to Leonardo Riella MD PhD, medical director of kidney transplantation at Mass General Hospital on receiving this year’s award for the abstract, “Gene-Edited Pig Kidney Xenotransplants in Humans: Record Survival and Mechanistic Insights,” recognized as the best overall abstract at ATC 2026. This recognition reflects the remarkable progress being made in xenotransplantation and our shared commitment to expanding access to lifesaving organs for patients with kidney failure. #organ #transplantation

Thank you to everyone who joined us at #BIO2026 for "Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage." We appreciated the thoughtful audience questions and engaging discussion on the progress being made to address the global organ shortage. Thanks to moderator Jonathan D. Grinstein , PhD, and our fellow panelists: • Michael Curtis, Ph.D., President & CEO, eGenesis • Cameron Lillie-Liberto, Kidney Disease Patient Advocate • Jesse Roach, M.D., Senior Vice President, Government Relations, National Kidney Foundation • Xiaoxi Wei, Ph.D. (Sofie), Ph.D., CEO & Co-Founder, X-Therma Inc. • David K. Yang, Partner, Lux Capital We're especially grateful to Cameron for sharing the patient perspective and reminding us of the urgent need for new solutions for individuals waiting for life-saving organ transplants. #BIO2026 #Xenotransplantation #OrganTransplantation #Biotech #Innovation

We're excited to welcome Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser on her appointment to Chief Commercial Officer. As eGenesis advances its clinical programs in kidney failure and acute-on-chronic liver failure, these leadership appointments strengthen the company's ability to execute through its next phase of growth. Glenn brings extensive experience across biotechnology, medtech, and specialty pharmaceuticals, including leadership in financing, IPO preparation, and strategic transactions. Jennifer has been instrumental in shaping eGenesis' business and commercial strategy and will now lead efforts to prepare the market for the company's pioneering organ transplantation programs. “eGenesis is entering a pivotal stage in our evolution as we prepare to advance our programs through clinical development and lay the foundation for future commercialization,” said Michael Curtis, Ph.D., Chief Executive Officer, eGenesis. Together, they will help advance our mission to transform the treatment of organ failure through human-compatible engineered organs and address the critical shortage of transplantable organs. Read our release: https://lnkd.in/eMxVAVJv #organ #transplantation

At #BIO2026, Mike Curtis, Ph.D., President & CEO of eGenesis, will join leaders across the transplantation ecosystem for a discussion on the clinical progress, challenges, and future potential of xenotransplantation to address the global organ shortage. Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage June 22, 2026 | 3:00 PM – 4:00 PM PT Room 24BC Panelists: • Jonathan D. Grinstein, Ph.D., Inside Precision Medicine (Moderator) • Michael Curtis, Ph.D., eGenesis • Cameron Lillie-Liberto, Kidney Disease Patient Advocate • Jesse Roach, M.D., National Kidney Foundation • Xiaoxi Wei, Ph.D., Ph.D., X-Therma Inc. • David K. Yang, Lux Capital With more than 800,000 Americans living with end-stage kidney disease and a persistent shortage of donor organs, the need for new solutions has never been greater. The discussion will explore how advances in genome engineering, transplantation science, and clinical development are bringing xenotransplantation closer to becoming a viable treatment option for patients awaiting lifesaving organs. Read our release: https://lnkd.in/e4ZpBuw9 #Xenotransplantation #OrganTransplantation #KidneyDisease #Biotechnology #BIO2026

The eGenesis team was honored to sponsor and attend the 2nd Richard Slayman Clinical Xenotransplantation Meeting held at NYU Langone Health, joining leaders from across transplantation, research, industry, government, and the patient community. The meeting highlighted the remarkable progress being made in xenotransplantation and the importance of continued collaboration among clinicians, scientists, regulators, patients, and advocates to expand access to lifesaving organ transplantation. Richard Slayman, the first patient to receive a transgenic porcine kidney transplant in March of 2024, demonstrated what is possible through courage, innovation, and partnership. His pioneering spirit, and the patients who have followed him, continue to inspire the work we do every day to advance new transplant solutions for patients in need. Just over a year later, the progress across #xenotransplantation has been remarkable. Thank you to Dr. Robert Montgomery, Dr. Macey Levan, and the entire NYU Langone Health team for bringing together the community working to shape the future of transplantation. We are proud to be part of this effort and remain committed to advancing the science and expanding access to transformative therapies for patients suffering from organ failure. #transplantation

Great discussion at the 2026 Wyss Institute at Harvard University Retreat. Our CEO Michael Curtis, joined George Church and Leonardo Riella MD for a conversation moderated by Angelika Fretzen on the future of #xenotransplantation and its potential to address the global organ shortage. Thanks to the Wyss Institute for bringing together leaders across science and medicine to advance ideas that could transform patient care. #WyssRetreat26 #eGenesis #Xenotransplantation #OrganTransplantation

Join eGenesis at the “Building Single-Cell RNA-seq Atlases: Concepts and Best Practices” workshop on June 4 from 2:00–3:30 PM at the Festival of Genomics Biodata and AI conference in Boston. Single-cell RNA-seq technologies are transforming how researchers characterize cellular diversity across tissues, organs, and disease states. This workshop will provide a practical introduction to building and applying single-cell RNA-seq atlases, including best practices for data integration, metadata standardization, iterative QC refinement, and defining cell types and cellular states at scale. The session will also feature a real-world case study on building and mining a single-cell atlas, alongside key open-source resources and tools supporting atlas development and translational research. Ángel Gálvez Merchán, Scientist and Computational Biologist at eGenesis, will host this workshop. More info about the event: https://lnkd.in/dJ2W_tCg #SingleCell #RNAseq #ComputationalBiology #FOGBoston

Powerful to see Tim Andrews’ story featured in USA TODAY, a moment that reflects how far #xenotransplantation has come, and where it’s headed. Tim’s journey from end-stage kidney disease, to receiving a genetically modified pig kidney, to ultimately a human transplant, highlights the real, near-term potential of engineered organs to give patients a second chance at life. At eGenesis, this is exactly the future we’re working toward. Making scalable organ transplantation a reality for the thousands of patients who otherwise may never receive one. Stories like this show what’s possible when bold science meets urgent patient need. Read the article: https://lnkd.in/dj-kjtvd #Xenotransplantation #Biotech #GeneEditing #Transplantation #Innovation

First-In-Human Porcine Kidney Transplant Trial Builds On Expanded Access Success A conversation between eGenesis CEO Michael Curtis, Ph.D., and Clinical Leader Executive Editor Abby Proch. Read the article: https://lnkd.in/gHs-KF2c #transplantation #biotech

April is National Donate Life Month, a time to recognize the power of organ donation and the lives it saves. Established by Donate Life America in 2003, this month is dedicated to raising awareness, encouraging donor registration, and honoring the individuals and families who have given the ultimate gift of life. At eGenesis, this mission deeply resonates with our work. Every day, we are focused on expanding access to life-saving organ transplantation and addressing the critical shortage that impacts millions of patients worldwide. Organ donation is one of the most profound acts of generosity. This month, we recognize: 🔹 Donors and their families, whose decisions have transformed lives 🔹 Patients and advocates continuing to raise awareness 🔹 The broader community working toward a future where no one dies waiting for a transplant Together, we can help build that future. Learn more here: https://lnkd.in/e3qAueHD #DonateLifeMonth #OrganDonation #Transplantation #Biotech #eGenesis